APOLLO
Research type
Research Study
Full title
A randomised, double-blind, placebo controlled, first in human study to investigate the safety, tolerability, and pharmacokinetic and pharmacodynamic response of SLN360 in subjects with elevated lipoprotein(a)
IRAS ID
286885
Contact name
Kausik Ray
Contact email
Sponsor organisation
Silence Therapeutics Plc
Eudract number
2020-002471-35
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
1 years, 0 months, 31 days
Research summary
The aim of the study is to learn about the safety and tolerability of a new experimental medicine called SLN360, in people with high levels of LP(a).
Lipoprotein(a)or Lp(a) for short is a particle made by the liver, which carries cholesterol, fats and proteins in the blood. The amount of Lp(a) a person’s body makes is determined by the genes passed down by their parents and it cannot be changed by lifestyle changes. Certain currently available medicines that are used to lower lipids (fat) levels in the blood can also lower Lp(a); however, some of these are less effective overall in people with high levels of Lp(a).
High levels of LP(a) have been shown to be associated with increased risk of developing heart disease and could contribute to development of diseases such as aortic stenosis (narrowing of the aortic valve opening), coronary artery disease (narrowing of the arteries that supply blood to the heart) and peripheral artery disease (narrowing of the arteries that supply blood to your arms and legs) or stroke (blockage of the arteries that lead to the brain).
SLN360 has the potential to lower Lp(a) in people with high levels in their blood.
Up to 88 people will take part in the study across three centres in the UK, USA and The Netherlands. There will be two parts to the study, each testing various dosing schedules. The study duration for each participant is expected to be for up to 8 months to a maximum of 12 months to look at longer term effects.
REC name
London - Brent Research Ethics Committee
REC reference
20/LO/1058
Date of REC Opinion
10 Dec 2020
REC opinion
Further Information Favourable Opinion